English (UK)
中文版Shanghai Fenglin Biomedical Development Co. Ltd 
Fenglin Biomedical Center (BioFM) is an innovation platform based in Xuhui Shanghai, which functions as the China soft-landing gateway for oversea bio-medical companies. It provides working spaces in downtown area in a flexible manner and helps clients increase their business value with professional services and by leveraging innovative resources including academics, hospitals, industries and venture capitals in the region. Different from the traditional accelerators and incubators, BioFM aims to be a boutique and unique service provider especially for bio-medical entrepreneurs, doctors, and scientists, while helping overseas companies and start-ups to develop their business in China quicker and better
Richard Tao
Mr / Project ManagerShanghai Henlius Biotech
Henlius (2696.HK) is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology and autoimmune diseases. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California, and commercial office in Frankfurt. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process.
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.
Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.
Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,
Mr. Jean-Baptiste Duval
VP International OperationsShanghai Huaota Biopharmaceutical
Our company focUnited Statesed on innovative drug discovery,Sticking to indevelop R&D,and we have very robUnited Statest pipeline and flexible bUnited Statesiness model.
吉雄 江
BDShanghai Innovative Research Center of Tradtional Chinese Medicine
SIRC is specialized in natural drug discovery from Chinese Medicine. It has a TCM data base including 270,000 prescriptions, 9,000 herbs and 50,000 herb-derived compounds. We provide the customized drug discovery based on natural herbs.
Grace Yin
DirectorShanghai J Rich Captial
J Rich Capital Inc. is an investment banking boutique with offices in Shanghai and Silicon Valley. Established in 2008, we specialize in mergers and acquisitions, capital raising, and asset management services within biotech, pharmaceutical, and real estate industries. Our expansive capital management capabilities as well as our deep understanding of the China market differentiate us from our peers in the financial industry.
佳 付
副总经理Shanghai Medicilon
CRO based in Shanghai
Ms. Sally Tang
Director of Business DevelopmentMingzhu Zhang
VP of Business DevelopmentDr. TAO YE
Director of business developmentShanghai MicroPort Medical
Top medical device company in China focused on cardiovascular, surgical robotics and ten more fields.
Responsive Web Design powered by 